Anti-ASGPR1 antibody

Anti-ASGPR1 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit monoclonal to ASGPR1

IHC-P

Mouse ASGPR1 / ASGR1

HL-1 antibody; ASGPR antibody; ASGPR1 antibody; CLEC4H1 antibody; Asgr antibody; HL-1 antibody; ASGPR1 antibody; Asgr-1 antibody; ASGPR antibody; ASGPR1 antibody; Asgr1 antibody; ASGR1 antibody; Asgr-1 antibody; CLEC4H1 antibody; Hs.12056 antibody; RP23-172M21.2 antibody; Asgr antibody

Rabbit IgG

This antibody was obtained from a rabbit immunized with purified, recombinant Mouse ASGPR1 / ASGR1 (rM ASGPR1 / ASGR1; NP_033844.1; Ser60-Asn284).

Monoclonal

0.2 μm filtered solution in PBS with 5% trehalose

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

The asialoglycoprotein receptor (ASGPR), an endocytotic cell surface receptor expressed by hepatocytes, is triggered by triantennary binding to galactose residues of macromolecules such as asialoorosomucoid (ASOR). ASGPR belongs to the long-form subfamily of the C-type/Ca2+ dependent lectin family. It is a complex of two noncovalently-linked and highly homologous subunits, a major 42 kDa glycoprotein ASGPR1(MHL-1) and a minor 51 kDa glycoprotein ASGR2 (MHL-2). ASGPR1 is synthesized as a type II transmembrane protein that contains a cytosolic N-terminal domain, a single transmembrane segment, and an extracellular domain which contains two important structural regions. The first is a stalk domain that contributes to noncovalent oligomerization, and the second is a Ca2+-dependent carbohydrate binding domain at the very C-terminus that is unusually stabilized by three ions. The research regarded that ASGPR1 could be targeted for anti- hepatitis B virus (HBV) drug development.

• Yang J, et al. (2006) Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication. J Viral Hepat. 13(3): 158-65.
• Li Y, et al. (2008) Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv. 5(4): 299-302.